Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat + Trastuzumab in HER2+ Metastatic Breast Cancer
NCT00567879Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2008
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of panobinostat in HER2-positive metastatic breast cancer, sponsored by Novartis. Started Apr 2008; status: terminated.
02
Drugs
panobinostat
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT00567879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00567879.